RE:Back from the AGM...Revenues for the year are going to be near $ 40M, base case scenario. However, this don't include any deals or new orders. As for the cost of R&D of the proteins, it's ridiculous when you see the potential return for the revenues.You guys can't imagine how Lucky we were to gwt back that Nantpro participation. We are just Lucky that Nantpharma have a problem with their heparin product, which is not related to us. The cost of developing IVIG is not high, considering it's a bio equivalence trial.